Laboratory Co. of America Holdings (NYSE:LH) Shares Sold by Inlet Private Wealth LLC

Inlet Private Wealth LLC trimmed its stake in Laboratory Co. of America Holdings (NYSE:LH) by 5.6% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 14,937 shares of the medical research company’s stock after selling 880 shares during the quarter. Inlet Private Wealth LLC’s holdings in Laboratory Co. of America were worth $3,425,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Marietta Wealth Management LLC lifted its holdings in shares of Laboratory Co. of America by 3.1% during the fourth quarter. Marietta Wealth Management LLC now owns 21,251 shares of the medical research company’s stock valued at $4,873,000 after purchasing an additional 638 shares during the last quarter. Everett Harris & Co. CA boosted its stake in shares of Laboratory Co. of America by 6.0% during the 4th quarter. Everett Harris & Co. CA now owns 32,354 shares of the medical research company’s stock valued at $7,419,000 after buying an additional 1,840 shares during the period. Custom Index Systems LLC boosted its position in Laboratory Co. of America by 8.9% during the fourth quarter. Custom Index Systems LLC now owns 4,554 shares of the medical research company’s stock valued at $1,044,000 after purchasing an additional 372 shares during the last quarter. Heck Capital Advisors LLC bought a new stake in shares of Laboratory Co. of America in the 4th quarter valued at approximately $44,000. Finally, Caprock Group LLC grew its position in Laboratory Co. of America by 30.0% in the fourth quarter. Caprock Group LLC now owns 5,394 shares of the medical research company’s stock worth $1,237,000 after acquiring an additional 1,244 shares in the last quarter. 95.94% of the stock is currently owned by institutional investors.

Laboratory Co. of America Stock Performance

Shares of NYSE:LH opened at $249.39 on Friday. The stock has a market capitalization of $20.86 billion, a P/E ratio of 48.24, a P/E/G ratio of 1.83 and a beta of 1.06. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.66. Laboratory Co. of America Holdings has a 1-year low of $191.97 and a 1-year high of $258.59. The business has a 50-day moving average price of $236.02 and a two-hundred day moving average price of $228.54.

Laboratory Co. of America Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 12th. Shareholders of record on Thursday, February 27th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.15%. The ex-dividend date of this dividend is Thursday, February 27th. Laboratory Co. of America’s dividend payout ratio is presently 55.71%.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Jefferies Financial Group reissued a “buy” rating and set a $275.00 price objective (up previously from $265.00) on shares of Laboratory Co. of America in a report on Tuesday, December 10th. UBS Group dropped their price objective on shares of Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating on the stock in a report on Tuesday. Evercore ISI upgraded Laboratory Co. of America from an “in-line” rating to an “outperform” rating and upped their target price for the company from $260.00 to $265.00 in a research note on Tuesday, January 7th. Hsbc Global Res upgraded shares of Laboratory Co. of America from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, Barclays lifted their price objective on Laboratory Co. of America from $234.00 to $249.00 and gave the company an “equal weight” rating in a report on Friday, October 25th. Four research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $261.77.

Insider Buying and Selling

In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 1,000 shares of Laboratory Co. of America stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $239.42, for a total value of $239,420.00. Following the transaction, the executive vice president now owns 2,670 shares of the company’s stock, valued at approximately $639,251.40. The trade was a 27.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Glenn A. Eisenberg sold 11,711 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $240.43, for a total transaction of $2,815,675.73. Following the sale, the executive vice president now directly owns 31,289 shares of the company’s stock, valued at $7,522,814.27. This represents a 27.23 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 24,572 shares of company stock valued at $5,915,209 over the last three months. Company insiders own 0.85% of the company’s stock.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.